Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY-NC 4.0Osteoporosis International

Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement

3 more authors
19 affiliations
  1. 1Département de Rhumatologie Sud, Centre Expert Des Métastases Osseuses (CEMOS), Institut de Cancérologie Des Hospices Civils de Lyon, Hôpital Lyon Sud, 165 Ch du Grand Revoyet, Pierre-Bénite, 69495 France
  2. 2INSERM UMR1033 – LYOS, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, 69100 France
  3. 3Centre de Recherche en Cancérologie de Lyon (CRCL), UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, 69100 France
  4. 4CHU Angers, Service de Rhumatologie, Angers, 49933 France
  5. 5INSERM, Regenerative Medicine and Skeleton, Univ Angers, Nantes Université, Oniris, RMeS, UMR 1229, Angers, 49000 France
  6. 6Garvan Institute of Medical Research, Sydney, Australia
  7. 7Medical College of Wisconsin, Milwaukee, USA
  8. 8Frankfurt Center of Bone Health and Endocrinology, Frankfurt, Germany
  9. 9Philipps-University of Marburg, Marburg, Germany
  10. 10Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
  11. 11Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
  12. 12FIRMO Foundation, Florence, Italy
  13. 13Department of Medicine, Clinica Universidad de los Andes, Universidad de los Andes, Santiago de Chile, Chile
  14. 14Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Melbourne, VIC Australia
  15. 15Rheumatology Office, Mohamed V University, Rabat, Morocco
  16. 16Dept. of Orthopedics, Medical University of Vienna, Vienna, Austria
  17. 17Department of Medicine, University of British Columbia, Vancouver, Canada
  18. 18Department of Gynaecology, Medical Faculty, Stellenbosch University, Western Cape, Stellenbosch, South Africa
  19. 19Osteoporosis Center, Hadassah Mount-Scopus University Hospital, Jerusalem, Israel

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a frequent hematological condition that occurs in later life. MGUS is associated with increased fragility fractures that mix individual osteoporotic risk factors, MGUS-related comorbidities, and direct MGUS bone impact such as senescence of plasma cells. This International Osteoporosis Foundation (IOF) position statement aims at evaluating the potential relationship between MGUS and fracture risk, as well as methods for evaluating bone involvement in MGUS. Finally, we propose the first bone clinical guidance for patients with MGUS to improve their bone health.

Background: Monoclonal gammopathy of undetermined significance is a prevalent hematological condition in adults, characterized by the presence of an abnormal monoclonal protein in the blood without concomitant symptoms or malignancy. MGUS is of considerable bone significance and contributes to fragility fractures in adults.

Methods: In this review, data pertaining to bone fragility were collected, including epidemiological fracture data in patients with MGUS, bone mineral density (BMD), bone microarchitecture, bone turnover marker, and bone histomorphometry data.

Results: Collectively, these findings suggest an elevated risk of fractures, especially in presence of osteoporotic risk factors or comorbidities, and a diminished BMD due to augmented bone resorption. Studies focusing on the treatment of this condition are limited.

Conclusion: Based on this analysis, we present the International Osteoporosis Foundation (IOF) position statement for bone evaluation and management of these patients. We recommend a risk-adapted treatment strategy. A proposal of bone clinical guidance dedicated to patients with MGUS is presented, suggesting bisphosphonates as the preferred treatment option.

Graphical abstract:

Related

  1. Cardiac Amyloidosis in Monoclonal Gammopathy of Undetermined Significance
    Samuel Copen, Stephen Copen
    CureusPeer-reviewedCC BY 4.0Full textCardiovascular medicinePMCEurope PMC
  2. Vertebral Fragility in Monoclonal Gammopathy of Undetermined Significance Despite Denosumab: Lessons From a Case
    Evangelia Papakitsou, Alexandos Gkiokas, Christos Zafeiris +2
    CureusPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  3. Monoclonal Gammopathy in Autoimmune Diseases: Marker, Consequence, Pathogenetic Factor—Or Coincidence?
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Suboptimal Response to Eculizumab in Renal‐Limited Thrombotic Microangiopathy Associated With Malignant Hypertension and Monoclonal Gammopathy: A Case Report
    Wenjuan Lei, Tianli Shi, Man Xu +1
    Clinical case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Clinical diagnostic patterns preceding the diagnosis of systemic light chain amyloidosis in patients with monoclonal gammopathy: a longitudinal, retrospective, cohort study
    Anita D'Souza, Duo Yu, Noel Estrada-Merly +3
    eClinicalMedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
BibTeX
@article{confavreux2026clinical,
  title = {{Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement}},
  author = {Cyrille B. Confavreux and Beatrice Bouvard and Robert Blank and Peyman Hadji and Emmanuel Biver and Jean-Jacques Body and Maria Luisa Brandi and Claudia Campusano and Peter R. Ebeling and Abdellah El Maghraoui and Gerold Holzer and David Kendler and Tobie de Villiers and René Rizzoli and A. Joseph Foldes},
  journal = {Osteoporosis International},
  year = {2026},
  month = sep,
  doi = {10.1007/s00198-026-08178-0},
  url = {https://doi.org/10.1007/s00198-026-08178-0},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Clinical guidance on evaluation and management of bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS): an IOF position statement
AU  - Cyrille B. Confavreux
AU  - Beatrice Bouvard
AU  - Robert Blank
AU  - Peyman Hadji
AU  - Emmanuel Biver
AU  - Jean-Jacques Body
AU  - Maria Luisa Brandi
AU  - Claudia Campusano
AU  - Peter R. Ebeling
AU  - Abdellah El Maghraoui
AU  - Gerold Holzer
AU  - David Kendler
AU  - Tobie de Villiers
AU  - René Rizzoli
AU  - A. Joseph Foldes
PY  - 2026
DA  - 2026/09/08
JO  - Osteoporosis International
DO  - 10.1007/s00198-026-08178-0
UR  - https://doi.org/10.1007/s00198-026-08178-0
AB  - Monoclonal gammopathy of undetermined significance (MGUS) is a frequent hematological condition that occurs in later life. MGUS is associated with increased fragility fractures that mix individual osteoporotic risk factors, MGUS-related comorbidities, and direct MGUS bone impact such as senescence of plasma cells. This International Osteoporosis Foundation (IOF) position statement aims at evaluating the potential relationship between MGUS and fracture risk, as well as methods for evaluating bone involvement in MGUS. Finally, we propose the first bone clinical guidance for patients with MGUS to improve their bone health.  Background: Monoclonal gammopathy of undetermined significance is a prevalent hematological condition in adults, characterized by the presence of an abnormal monoclonal protein in the blood without concomitant symptoms or malignancy. MGUS is of considerable bone significance and contributes to fragility fractures in adults.  Methods: In this review, data pertaining to bone fragility were collected, including epidemiological fracture data in patients with MGUS, bone mineral density (BMD), bone microarchitecture, bone turnover marker, and bone histomorphometry data.  Results: Collectively, these findings suggest an elevated risk of fractures, especially in presence of osteoporotic risk factors or comorbidities, and a diminished BMD due to augmented bone resorption. Studies focusing on the treatment of this condition are limited.  Conclusion: Based on this analysis, we present the International Osteoporosis Foundation (IOF) position statement for bone evaluation and management of these patients. We recommend a risk-adapted treatment strategy. A proposal of bone clinical guidance dedicated to patients with MGUS is presented, suggesting bisphosphonates as the preferred treatment option.  Graphical abstract:
SN  - 0937-941X
SN  - 1433-2965
ER  -